BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
See today's BioWorld
Home
» ThromboGenics' Ocriplasmin Filing on Track in Europe, U.S.
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
ThromboGenics' Ocriplasmin Filing on Track in Europe, U.S.
Aug. 24, 2011
By
Cormac Sheridan
No Comments
Six-month follow-up data from ThromboGenics NV's Phase III program for its ophthalmology drug Ocriplasmin (microplasmin) confirm top-line data it reported last year and keep the drug on track for a regulatory filing in the coming weeks.
BioWorld